Table 2 Baseline tumor and treatment characteristics
Primary lung cancer | Metastatic lung tumor | Total | |
|---|---|---|---|
Number | 172 tumors | 57 tumors | 229 tumors |
Tumor diameter (cm) | 2.2 (range: 0.9-4.7) | ||
≤ 2.0 | 73 (42%) | 27 (47%) | 100 (43%) |
2.1-3.0 | 75 (43%) | 23 (40%) | 98 (42%) |
3.1-5.0 | 24 (13%) | 7 (12%) | 31 (13%) |
Tumor appearance | |||
Mainly solid component | 160 (93%) | 57 (100%) | 217 (94%) |
Mainly ground-glass opacity | 12 (6%) | 0 (0%) | 12 (5%) |
SUVmax on staging FDG-PET | 5.9 (range: 0.6-22.8) | ||
< 5.9 | 53 (50%) | 4 (57%) | 57 (50%) |
≥ 5.9 | 53 (50%) | 3 (42%) | 56 (50%) |
Prescription dose | |||
BED10 ≤ 105 Gy | 84 (48%) | 12 (21%) | 96 (41%) |
BED10 > 105 Gy | 88 (51%) | 45 (78%) | 133 (58%) |
Date of treatment | |||
2001-2005 | 76 (44%) | 39 (68%) | 115 (50%) |
2006-2011 | 96 (55%) | 18 (31%) | 114 (50%) |